Share on StockTwits

Momenta Pharmaceuticals (NASDAQ:MNTA) announced its earnings results on Thursday. The company reported ($0.51) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.46) by $0.05, Analyst Ratings Network reports. The company had revenue of $11.00 million for the quarter, compared to the consensus estimate of $11.22 million.

Several analysts have recently commented on the stock. Analysts at Maxim Group initiated coverage on shares of Momenta Pharmaceuticals in a research note on Thursday, June 5th. They set a “buy” rating and a $17.00 price target on the stock. On the ratings front, analysts at Goldman Sachs initiated coverage on shares of Momenta Pharmaceuticals in a research note on Monday, June 2nd. They set a “buy” rating and a $19.00 price target on the stock. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $19.20.

Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) opened at 11.08 on Thursday. Momenta Pharmaceuticals has a 1-year low of $9.85 and a 1-year high of $19.90. The stock’s 50-day moving average is $11.80 and its 200-day moving average is $13.64. The company’s market cap is $570.1 million.

Momenta Pharmaceuticals, Inc (NASDAQ:MNTA) is a biotechnology company specializing in the characterization and process engineering of complex molecules.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.